Summit Therapeutics (NASDAQ:SMMT) WCLC Update Conference Call September 08, 2025 08:00 AM
Company Participants
Dave Gancarz – Chief Business & Strategy Officer
Howard (Jack) West – Vice President of Clinical Development
Manmeet Soni – COO, CFO & Director
Urte Gayko – Chief Regulatory, Quality & Pharmacovigilance Officer
Robert Duggan – Co-CEO & Executive Chairman
Conference Call Participants
Yigal Nochomovitz – Citigroup Inc., Research Division
Salveen Richter – Goldman Sachs Group, Inc., Research Division
Bradley Canino – Guggenheim Securities, LLC, Research Division
Asthika Goonewardene – Truist Securities, Inc., Research Division
Cory Kasimov – Evercore ISI Institutional Equities, Research Division
Mohit Bansal – Wells Fargo Securities, LLC, Research Division
Kelsey Goodwin – Piper Sandler & Co., Research Division
Daina Graybosch – Leerink Partners LLC, Research Division
Yuxi Dong – Jefferies LLC, Research Division
Reni Benjamin – Citizens JMP Securities, LLC, Research Division
Xiaochuan Dai – UBS Investment Bank, Research Division
Presentation
Operator
Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Summit Therapeutics Update Call. [Operator Instructions]
It is now my pleasure to turn today’s call over to Dave Gancarz, Chief Business and Strategy Officer. Dave, please go ahead.
Dave Gancarz
Chief Business & Strategy Officer
Good morning and thank you for joining us. We issued a press release yesterday morning relating to the Phase III HARMONi data featuring ivonescimab presented as a part of the Presidential Symposium at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer, otherwise known as World Lung or WCLC 2025. The press release is available on our website, www.smmttx.com. Our 8-K was filed today and is available on our website and via the SEC’s website. Today’s call is being simultaneously webcast, and an archived replay will also be made available later today on our website.
Read the full article here
